drugset / Trial / NCT03533153

Intravenous MSC Therapy on Ischemia-Reperfusion Injury in Patients With Myocardial Infarction

NCT03533153

RandomizedParallel-groupSingle-blindTreatment

Summary

The investigators scheduled to assess the value of intravenous injection of WJ-MSC in patients with ST-segment elevation myocardial infarction (STEMI).

Timeline

Start
2021-03-01
Primary completion
2023-12-30
Completion
2025-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject WJ-MSC Cell therapy 1e+08 cells Intravenous
Background Aspirin Small molecule 100 mg
Background Clopidogrel Small molecule 75 mg
Background Ticagrelor Small molecule 90 mg

Indications